Claritev’s latest research update centers on a revised price target of US$74, with the core model assumptions for fair value, discount rate and revenue growth essentially held in place. Analysts ...
Good morning, ladies and gentlemen, and welcome to the Humacyte's Third Quarter Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I'll now turn ...
Hosted on MSN
Citigroup Upgrades Claritev (CTEV)
Fintel reports that on October 21, 2025, Citigroup upgraded their outlook for Claritev (NYSE:CTEV) from Neutral to Buy. Analyst Price Forecast Suggests 22.59% Upside As of September 30, 2025, the ...
A drastic new procedure, which inflicts tiny fractures to the ribs, emerges at the forefront of body modification. A drastic new procedure, which inflicts tiny fractures to the ribs, emerges at the ...
Imagine a world where surgeons are guided by AI to perform complex operations with the precision of world-class experts and where life-saving surgery reaches remote corners of the globe through ...
- Humacyte plans to advance CTEV into first-in-human study in CABG - DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results